Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 21, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Repurchased: 3,115,000 Ordinary shares.
- Repurchase Price: 1,345.1456 pence per share.
- Treasury Shares Held: 404,832,158 shares (representing 7.20% of total voting rights).
- Shares in Issue: 5,618,848,824 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the September 21, 2007 transaction. Consequently, the total number of shares in issue (excluding Treasury shares) remains the denominator for voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory conformity statement regarding the Transparency Directive.
Investor Verification Checklist
- Verify the total number of shares in issue (5,618,848,824) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (404,832,158) and its impact on the 7.20% voting rights representation.
- Review the authorization details from the May 23, 2007 Annual General Meeting to ensure the repurchase was within approved limits.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings metrics.